2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

1473 Harmonization of single-cell resistance states defines clinically actionable programs in acute myeloid leukemia

Vikram Dhillon, DO, MBA, Jeff Justin Aguilar, MD, MBA2, Asmita Shukla, MD3, Dakshin Padmanabhan, MD4, Sikander Chohan, MD5, Gregory Dyson6, Suresh Kumar Balasubramanian, MD7
1 Karmanos Cancer Institute, Detroit, United States
2 Karmanos Cancer Institute, Detroit, United States
3 Karmanos Cancer Institute, Detroit, United States
4 Karmanos Cancer Institute, Detroit, United States
5 Karmanos Cancer Institute, Detroit, United States
6 Karmanos Cancer Institute, Detroit, United States
7 Karmanos Cancer Institute, Detroit, United States

Background: Venetoclax (VEN) resistance in acute myeloid leukemia (AML) has been linked to monocytic differentiation, leukemia stem-cell states, and metabolic reprogramming, but published signatures have not been reconciled or translated to large bulk RNA-sequencing cohorts. We asked whether single-cell resistance signatures converge on shared programs measurable in bulk transcriptomes and whether these define AML subgroups with distinct genotypes, VEN responses, and therapeutic vulnerabilities.

Methods: Published AML single-cell RNA-sequencing datasets were harmonized, retaining blast/myeloid cells. Reported stem-cell and VEN-resistance signatures were scored, grouped by correlation, and factorized by nonnegative matrix factorization into consensus programs. Full-transcriptome references were deconvolved into BeatAML2 and TCGA-LAML using BayesPrism. Program abundance was associated with phenotype, morphology, cytogenetic risk, mutations/co-mutation class, ex-vivo VEN response, broader drug sensitivity, and survival. Stability, reconstruction, inter-program correlation, and cross-cohort concordance underwent pre-specified quality control.

Results: The atlas included 129,401 cells from 51 patients, with 56,031 blast/myeloid cells used for derivation. Eighteen published signatures consolidated into 12 correlated modules and 6 stable programs (R²=0.862; stability 0.980±0.039), projected into 707 BeatAML2 transcriptomes (367 with ex vivo VEN response).

The granulocytic/favorable-risk program was VEN-sensitive, enriched for IDH2 and STAG2 and depleted of RUNX1, and RAS-pathway mutations. The monocytic program, the largest and predominant VEN-resistant state, was enriched for NRAS, KRAS, PTPN11, ASXL1, RUNX1, and inv(16)/t(16;16), and depleted of NPM1, CEBPA, GATA2, WT1, and IDH1. The proliferative/Ox-Phos program was enriched for CEBPA (highest biallelic frequency) and TP53, with NPM1, FLT3-ITD, DNMT3A, IDH1/2, and TET2 absent. The erythroid/megakaryocytic-progenitor (E/M) program marked adverse-risk, secondary-type disease with complex karyotype, chromosome 7 abnormalities, and inv(3)/t(3;3), and was enriched for BCOR, RUNX1, SRSF2, IDH2, JAK2, PHF6, and RAD21 but depleted of NPM1, NRAS/KRAS, and DNMT3A. The primitive stem-like program showed the greatest VEN sensitivity, with NPM1/FLT3-ITD co-occurrence, frequent signaling alterations, and enrichment for NPM1, GATA2, WT1, and IDH1 but depletion of RAS, ASXL1, RUNX1, and SRSF2. The immune/cDC-like program was low-abundance, associated with BCORL1 and CCND3, and lacked a VEN-response phenotype.

Resistance programs coexisted in 154/707 patients (22%), and combinations had distinct phenotypes. Granulocytic-with-primitive was most VEN-sensitive (ρ=−0.638; p=2.87×10?4³), whereas granulocytic-with-monocytic conferred resistance (ρ=0.490; p=1.62×10?²³), indicating that VEN response reflects composite lineage-state architecture. Eight resistant samples were unexplained by the six-program taxonomy and instead showed enrichment of the E/M program (p=7.96×10?5). Independent NMF recovered a stable heme/megakaryocytic program (ITGA2B, GATA1, MPL, SLC40A1, ANK1, TFR2; heme-metabolism FDR=2.34×10?4). Cohort-wide, it was enriched in BCOR-, RUNX1-, and SRSF2-mutated AML and more abundant in chromatin/spliceosome-only than monocytic-route genotypes (0.225 vs 0.113; p=1.20×10?6), supporting an alternative to monocytic resistance.

Drug profiling identified 302 program-drug associations across 154 agents. The monocytic program was the most MEK-sensitive state (selumetinib ρ=−0.473, FDR=7.02×10?²4; trametinib ρ=−0.349, FDR=2.49×10?¹³; mean MEK-class ρ=−0.41), with additional sensitivity to panobinostat (ρ=−0.506; FDR=1.35×10?¹7), rapamycin, and MK-2206, whereas the granulocytic program was resistant to both MEK inhibitors, supporting program-specific treatment selection. The E/M route showed distinct vulnerability to IGF1R inhibition and fatty-acid oxidation blockade (NVP-AEW541 ρ=−0.370, FDR=0.043; etomoxir ρ=−0.368, FDR=0.044).

Conclusion: Harmonization of published single-cell resistance signatures produced a clinically interpretable VEN-response taxonomy measurable from bulk RNA sequencing. VEN response reflects composite lineage-state architecture rather than a single resistance program, with a dominant monocytic, RAS/signaling-linked route and a previously unrecognized, genotype-linked E/M alternative associated with chromatin/spliceosome mutations and distinct metabolic vulnerabilities.

Vikram Dhillon, DO, MBA: No relevant conflicts of interest to declare.